# Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma

> **NCT04233697** · PHASE1 · WITHDRAWN · sponsor: **Columbia University**

## Conditions studied

- Lymphoma, T-Cell

## Interventions

- **DRUG:** Copanlisib
- **DRUG:** Romidepsin

## Key facts

- **NCT ID:** NCT04233697
- **Lead sponsor:** Columbia University
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-02
- **Primary completion:** 2022-07-30
- **Final completion:** 2023-07-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Investigator left institution
- **Last updated:** 2020-08-13

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04233697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04233697, "Copanlisib in Combination With Romidepsin in Patients With Relapsed or Refractory Mature T-cell Lymphoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04233697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*